Hematopoietic Cell Transplantation as Treatment for Blood Cancers: The Team Approach (Participant)

Credit Available: ASWB, CABRN, NP

 

Enroll in this Course

FREE

access until October 16, 2025 12:00 am

 

Enroll Now

Activity Description

Awaiting it from LLS.

Time to Complete Activity: 1.75 hours

This course is available from:

September 26, 2024 until October 16, 2025

Course Instructors

Ran Reshef, MD MSc Speaker

Professor of Medicine, Deputy Director, Blood and Marrow Transplantation and Cell Therapy Program, Division of Hematology/Oncology, Columbia University Irving Medical Center, Columbia University Vagelos College of Physicians & Surgeons, New York, NY

David Sabatino, PharmD, BCOP Speaker

Clinical Pharmacy Manager, Stem Cell Transplant/ Myeloma,  NewYork-Presbyterian Hospital, Columbia University Irving Medical Center,  New York, NY

Tricia Skvarce, PA-C Speaker

Physician Assistant, Blood and Marrow Transplant, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center,  New York, NY

Muyun Zhao, LMSW Speaker

Social Worker, Outpatient Hematology Oncology & BMT Program, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY

Target Audience

Oncology nurse practitioners, nurses, and social workers involved in the care of patients with hematopoietic stem cell transplantation (HSCT).

Course Content Level for Social Workers — all levels

Format: Non-interactive recorded webinar

Educational Objectives
After completing this activity, the participant should be better able to:

• • Describe the types of hematopoietic cell transplantation used in the treatment of blood cancers, including autologous, allogeneic and reduced-intensity allogeneic stem cell transplantation

  • Identify the methods of stem cell collection used in patients with blood cancers.

  • Explain the overarching goals of hematopoietic cell transplantation for all types of blood cancers

  • Explain hematopoietic cell transplantation as a treatment option for blood cancers

  • Describe strategies to manage treatment side effects as well as potential long-term and late effects of hematopoietic cell transplantation

  • Describe the pharmacist’s role in managing patients undergoing hematopoietic cell transplantation

Accreditation, Support and Credit

Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.75 continuing education contact hours through the California Board of Registered Nursing.

Social Worker Continuing Education

The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.75 clinical continuing education credits.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.75 clinical CE contact hours for this activity.

Nurse Practitioner Continuing Education

This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to XX contact hours of accredited education.

Support Statement

There is no commercial support associated with this CE activity.

Providers

This activity is provided by The Leukemia & Lymphoma Society.

Disclosure of Conflicts of Interest Policy

All persons who may impact the content of a CE activity, including faculty and planners, are required to fully disclose current and recent financial relationships with commercial interests. A conflict of interest may be considered to exist if such a person has financial relationships with the grantor or any non-eligible entities (commercial interests) that may have a direct impact on the content of the program. Financial relationship is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support. Recent is defined as within the past 24 months. The participants in this CE activity must be made aware of any such financial relationship(s). This disclosure policy is intended to protect all parties involved from any potential conflict of interest that may arise.

Faculty Disclosures

Ran Reshef, MD MSc, has financial relationships with the following companies:
Advisory Group/Consultant: Allogene, Autolus, BayerGilead Sciences, Incyte, Orca Bio, Quell Biotherapeutics, Sana Biotechnology, Synthekine, TScan.
Clinical Investigator: Abbvie, Atara Biotherapeutics, BMS, Cabaletta, CareDx, Genentech, Gilead Sciences, Incyte, Immatics, Johnson & Johnson, Precision Biosciences, Sanofi, Synthekine, Takeda, and TCR2, TScan.

David Sabatino, PharmD, BCOP, has no financial relationships with ineligible companies.

Tricia Skvarce, MSHS, PA-C, has no financial relationships with ineligible companies.

Muyun Zhao, LMSW, has no financial relationships with ineligible companies.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated.

If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@kimeglobal.com.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.